Investigating a protein's role in heart failure and cardiac remodeling
Official title: RECK in Adverse Cardiac Remodeling and Heart Failure
Funded at Harry S. Truman Memorial VA Hospital · NIH-10911046 · Data updated 2026-11-12
This study is looking at how a protein called RECK affects heart failure in older adults and whether changing its levels can help improve heart function and keep patients out of the hospital.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harry S. Truman Memorial VA Hospital NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| NIH project number | 5I01BX005845-03 |
| Project ID | NIH-10911046 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults, particularly those over 65, who are experiencing heart failure or related cardiac issues.
✕Less likely to help
Patients under 65 years of age or those without heart failure or significant cardiac conditions may not benefit from this research.
What this research studies
This research focuses on understanding how a specific protein, RECK, influences heart failure and adverse cardiac remodeling in older adults. It examines the mechanisms by which RECK inhibits harmful processes in the heart, particularly those triggered by hypertension and aortic valve stenosis. The study aims to explore how manipulating RECK levels could potentially improve heart function and reduce hospital readmissions for heart failure patients. By analyzing both in vivo and in vitro models, the research seeks to uncover new therapeutic strategies for managing heart failure.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve heart health and reduce hospitalizations for older patients with heart failure.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways for heart failure treatment, indicating potential for success in this approach.
Where this research is happening
-
Harry S. Truman Memorial VA Hospital
Columbia, United States Active
Researchers
- Principal investigator: Bysani, Chandrasekar — Harry S. Truman Memorial VA Hospital
- Study coordinator: Bysani, Chandrasekar
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.